English

RLS GLOBAL AB (publ) INTERIM REPORT, Q3, 2020

Report this content

JULY 1st - SEPTEMBER 30th

  • Net sales amounted to KSEK 793 (KSEK 245)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -5,6  (MSEK -6,2)
  • Earning per share before dilution at SEK -0,08 (SEK-0,11)
  • Cash flow from operating activities amounted to MSEK -4,2 (MSEK-7,4)
  • Liquid assets at the end of the period MSEK 25,9 ( MSEK 53,7)
  • Equity ratio was 90 % (86 %)
 

JANUARY 1st - SEPTEMBER 30th

  • Net sales amounted to MSEK 1,9 (MSEK 0,97)

  • Earnings before interest and taxes (EBIT) amounted to MSEK -15,0 (MSEK-17,8)
  • Earning per share before dilution at SEK -0,23 (SEK -0,30)
  • Cash flow from operating activities amounted to MSEK -15,2 (MSEK -19,2)
  • Liquid assets at the end of the period MSEK 25,9 (MSEK 53,7)
  • Equity ratio was 90 % (86%)
 

SUMMARY OF EVENTS DURING THIRD QUARTER

  • The ChloraSolv patent was approved in Canada.

  • ChloraSolv is approved also in Region Skåne.  
  • Recurrent sales in all regions where ChloraSolv is approved.
 

SUMMARY OF EVENTS AFTER THIRD QUARTER

  • RLS participates in EWMA, the European Wound Conference which this year is digital. Associated Professor, Chief Physician Jan Apelqvist will present an abstract from the ChloraSolv01 study.

 

​​​​​​​COVID-19

  • In the current situation, the Board has considered the impact of different possible future Covid-19 related scenarios.

  • Since the healthcare sector is so extremely strained under the prevailing circumstances, all processes take longer which affects our market penetration and other activities, resulting in RLS focusing even more on R&D projects.
     

TRADING PLACE AND CERTIFIED ADVISER
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

The Interim Report Q3, 2020 is enclosed and is also available at https://rls.global/investor/regulatory-information/  

PUBLICATION
This information was submitted for publication through the agency of the above contact person, at 09.00 CET on November 12th, 2020.

CONTACT INFORMATION
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop product within wound care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North Growth Market with Redeye Aktiebolag as the Certified Advisor,
phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

 

Tags:

RLS Wound Care chlorasolv RLS Global

Subscribe

Documents & Links